Investigational therapies

Arcutis Biotherapeutics, Inc. is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.

Explore Our Pipeline
Pipeline

Our pipeline

Arcutis has built a broad and deep dermatology pipeline.

Roflumilast cream (ARQ-151) 0.15%

Topical

Phosphodiesterase 4 (PDE4) inhibitor
Disease state Plaque Psoriasis (Ages 2-5)
Phase
  • P
  • 1
  • 2
  • 3
  • R
 Investigational therapy Roflumilast cream (ARQ-151) 0.3%
Disease state Atopic dermatitis (Ages 3-24 months)
Phase
  • P
  • 1
  • 2
  • 3
  • R
 Investigational therapy Roflumilast cream (ARQ-151) 0.05%

Biologic

CD200 receptor (CD200R) agonist
Disease state Atopic dermatitis
Phase
  • P
  • 1
  • 2
  • 3
  • R
 Investigational therapy CD200R agonist (ARQ-234)

P = Preclinical
R = Submitted for FDA Review

Arcutis Biotherapeutics logo

This website is intended for US healthcare professionals only. There may be information included that pertains to an investigational therapy or formulation that has not yet been approved for use in your country. The safety and efficacy of investigational therapies and/or formulations and/or uses have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This information is as of 10/2025 to the best of the Company’s knowledge and Arcutis assumes no obligation to update this information.

© 2025 Arcutis Biotherapeutics, Inc. All rights reserved. MED0001 v3.0 10/2025.